Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019
American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e612-e616
DOI: 10.1055/a-1925-2017 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Buonomo A Riccardo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II Naples, Naples, Italy. Hauptthemen laut MEDLINE: Pregnancy Complications, Infectious, Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objective
Our objective was to evaluate the safety and efficacy of casirivimab/imdevimab therapy in pregnant women with severe coronavirus disease 2019 (COVID-19) requiring oxygen therapy. Study Design This was a prospective case series study aimed to evaluate the safety and efficacy of casirivimab/imdevimab therapy in unvaccinated pregnant women with severe COVID-19. Inclusion criteria were severe acute respiratory syndrome coronavirus 2 infection documented with polymerase chain reaction, pregnancy, severe COVID-19 requiring oxygen therapy, duration of symptoms of 10 days or less, and able to provide informed consent. Vaccinated women and those with mild-to-moderate disease were excluded from the study. Included patients received casirivimab and imdevimab as a single intravenous dose of 4,000/4,000 mg. Women were also treated with low molecular weight heparin, steroids, and antibiotics, if necessary. The primary outcome was maternal death. Secondary outcomes were the rate of adverse events during infusion or within 72 hours and the rate of abortion.
Results
Thirteen hospitalized unvaccinated pregnant women with severe COVID-19 requiring oxygen and treated with casirivimab/imdevimab were included in the study. We observed no maternal death, and no patients required intubation or admission to the intensive care unit. No abortion or fetal loss was recorded. Nine pregnancies were still ongoing, and there were three cesarean deliveries and one vaginal delivery. Two were preterm deliveries (at 31 and 34 weeks), and two were term deliveries.
Conclusion
Casirivimab/imdevimab therapy may be considered as a therapy in unvaccinated pregnant women with severe COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II Naples, Naples, Italy.
- Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.
Zitieren
APA
Riccardo, B. A., Gabriele, S., Nunzia, E., Isabella, D. F., Biagio, P., Maria, F., Emanuela, Z., Agnese, G., Nicola, S. M., Giulio, V., Riccardo, S., Giuseppe, B., & Ivan, G. (2024). Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019. American Journal of Perinatology, 41(S 01 S 01), e612-e616. https://doi.org/10.1055/a-1925-2017
Vancouver
Riccardo BA, Gabriele S, Nunzia E, Isabella DF, Biagio P, Maria F, et al. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019. American Journal of Perinatology. 2024;41(S 01 S 01):e612-e616. doi:10.1055/a-1925-2017
BibTeX
@article{Riccardo2024,
author = {Riccardo, Buonomo A and Gabriele, Saccone and Nunzia, Esposito and Isabella, Di Filippo and Biagio, Pinchera and Maria, Foggia and Emanuela, Zappulo and Agnese, Giaccone and Nicola, Schiano M and Giulio, Viceconte and Riccardo, Scotto and Giuseppe, Bifulco and Ivan, Gentile},
title = {Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019},
journal = {American Journal of Perinatology},
year = {2024},
volume = {41},
number = {S 01 S 01},
pages = {e612--e616},
doi = {10.1055/a-1925-2017}
}
EUVIMED